Abstract
Authors summarise possible caveats in a treatment of coronary artery disease (CAD). In the first line they underline proper indicationfor coronary revascularization based on a prove of myocardial ischemia.
Further important point is adequate lipid-loweringtherapy leading to atherosclerosis regression. Lipid-lowering therapy is frequently used in insufficient doses not leading to therequired target levels for secondary prevention in the patients with CAD.
But only those targets levels lead to regression ofcoronary atherosclerosis and then to decrease of the risk for ischemic coronary events.